Trials / Withdrawn
WithdrawnNCT03613402
BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Portola Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Part 1 - Evaluate the real-world implementation of extended prophylaxis with betrixaban in the acutely ill hospitalized medical population Part 2 - Describe patterns of Venous thromboembolism (VTE) prophylaxis in acutely ill medical patients who qualify for extended VTE prophylaxis
Conditions
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2020-01-01
- Completion
- 2020-01-01
- First posted
- 2018-08-03
- Last updated
- 2023-02-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03613402. Inclusion in this directory is not an endorsement.